Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Sino Medical, noting its high PE ratio compared to industry averages [1][2] - As of May 6, Sino Medical's stock closed at 9.89 yuan, with a PE ratio of 665.98, marking a new low in 20 days, and a total market capitalization of 4.089 billion yuan [1] - The average PE ratio for the medical device industry is 48.90, with a median of 36.41, positioning Sino Medical at the 120th rank within the industry [1][2] Group 2 - As of March 31, 2025, Sino Medical had 11,044 shareholders, an increase of 381 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company's main business focuses on the research, production, and sales of high-end interventional medical devices, primarily coronary stent systems and balloon dilation catheters [1] - The latest quarterly report for Q1 2025 shows Sino Medical achieved a revenue of 101 million yuan, a year-on-year increase of 10.75%, and a net profit of 2.9693 million yuan, reflecting a significant year-on-year growth of 277.50% with a gross margin of 59.66% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Sainuo Medical, which has a significantly high PE ratio compared to its industry peers [1][2] - As of April 21, Sainuo Medical's closing price was 9.41 yuan, with a PE ratio of 2557.77, marking a new low in 12 days, and a total market capitalization of 3.891 billion yuan [1] - The average PE ratio for the medical device industry is 47.69, with a median of 29.88, positioning Sainuo Medical at the 121st rank within the industry [1][2] Group 2 - Sainuo Medical specializes in the research, development, production, and sales of high-end interventional medical devices, with its main products including coronary stent systems and balloon dilation catheters [1] - The company's primary revenue source is the coronary drug-eluting stent system, and it has been recognized as a "Key Laboratory of Tianjin" and "Tianjin Enterprise Technology Center" [1] - For the third quarter of 2024, Sainuo Medical reported an operating income of 318 million yuan, a year-on-year increase of 30.20%, while the net profit was -6.74 million yuan, reflecting a year-on-year decline of 83.84%, with a gross profit margin of 61.29% [1]

序号股票简称PE(TTM)PE(静)市净率总市值(元)121赛诺医疗2465.352465.354.3737.50亿行业平均 45.9448.384.71101.41亿行业中值29.6428.792.3545.52亿1天益医疗-2672.56-2672.561.6719.88亿2硕世生 物-1835.15-1835.151.1537.91亿3诺唯赞-549.11-549.112.5299.35亿4博晖创新-335.30-206.443.6951.46亿5康 泰医学-262.5830.812.6851.07亿6华大基因-197.28215.792.04200.47亿7奥精医疗-108.26-108.261.3819.61亿 8睿昂基因-79.59-79.591.2411.51亿9热景生物-60.65-60.653.33108.69亿10华大智造-52.74-52.743.96315.97 亿11中红医疗-48.32-32.870.7743.02亿 来源：金融界 4月16日，赛诺医疗今日收盘9.07元，下跌3.41%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到2465.35倍，总市值37.50亿 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Sino Medical, indicating a significant disparity between its high PE ratio and the industry average [1][2] - As of April 10, Sino Medical's closing price was 9.21 yuan, with a PE ratio of 2503.41, significantly higher than the industry average of 46.15 [1][2] - The company's total market capitalization stands at 3.808 billion yuan, ranking it 121st in the medical device industry [1][2] Group 2 - Sino Medical specializes in the research, production, and sales of high-end interventional medical devices, with its main products being coronary stent systems and balloon dilation catheters [1] - The latest financial report for Q3 2024 shows a revenue of 318 million yuan, representing a year-on-year increase of 30.20%, while the net profit was a loss of approximately 6.74 million yuan, a year-on-year decline of 83.84% [1] - The gross profit margin for the company is reported at 61.29% [1]